Resumen
Controlling excessive weight has been recognized as an improvement in quality of life. Obesity is considered a disease in which there is an inadequate response from the brain to prevent emaciation. Consuming excess calories excessively causes excessive accumulation of body fat. Overweight (not obesity) is defined as a BMI of 25.0 to 29.9. Class 1 obesity (low risk), if the BMI is 30 to 34.9. Class 2 obesity (moderate risk), if the BMI is 35 to 39.9. Class 3 obesity (high risk), if the BMI is equal to or greater than 40.
Citas
World Health Organization. Obesity and overweight. Newsroom. FactSheets. 2022, June 9. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
National Heart, Lung, and Blood Institute. ¿Qué es el síndrome metabólico? NHLBI Health topics. May, 2022. https://www.nhlbi.nih.gov/es/salud/sindrome-metabolico
Revolution Medical Clinic. Ali Zentner. https://www.revolutionmedicalclinic.com/ali-zentner [s.d.].
Statista Research Department. Principales problemas de salud según la opinión pública en todo el mundo en 2022. 2023. https://es.statista.com/estadisticas/910907/principales-problemas-de-salud-en-opinion-de-la-poblacion-a-nivel-mundial/
Trust for America’s Health. Reports. 2023, June. https://www.tfah.org/reports/
Statista Research Department. Statista. Empowering people with data. = Datos e indicadores de 170 sectores de más de 150 países. 2023, March. https://es.statista.com/
Gobierno de Guatemala. MSPAS. En Guatemala el 29% de adolescentes padece de sobrepeso y el 8.40% de obesidad. Comunicado de prensa Nov. 9, 2022. https://prensa.gob.gt/comunicado/en-guatemala-el-29-de-adolescentes-padece-de-sobrepeso-y-el-840-de-obesidad
Rubino, D., Abrahamsson, N., Davies, M. et. al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial. JAMA, 2021, April; 325(14): 1414-1425. DOI: 10.1001/jama.2021.3224
Chen, S. Trial results position Mounjaro for weight loss drug approval. diaTribeLearn. Making sense of diabetes. 2023, April. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval
Jastreboff, A.M., Aronne, L.J., Ahmand, N.N., et.al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, July; 387: 205-216. DOI: 10.1056/NEJMoa2206038 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Wilding, J., Batterham, R.L., Calanna, S., et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, March; 384: 989-1002. DOI: 10.1056/NEJMoa2032183 https://www.nejm.org/doi/10.1056/nejmoa2032183.
Copyright
License
Copyright (c) 2023 Jorge Tulio Rodríguez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License 4.0 (CC BY-NC_SA 4.0) that indicates: a) It is allowed that others share the work, with an acknowledgement of the work's authorship and initial publication in this journal, b) The work may not be used for commercial purposes, c) If it's remixed, transformed, or built upon the material, one must distribute the contributions under the same license as the original
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, website or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
